BioCentury
ARTICLE | Clinical News

Immunomedics reports Phase I/II metastatic breast cancer data

May 17, 2018 8:46 PM UTC

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

Immunomedics added $1.39 to $20.90 on Thursday. The data were released after market close on Wednesday...